Table 4 Univariate and multivariate analyses of predictive factors for successful maintenance with steroid-sparing immunosuppressant monotherapy in patients with anti-HMGCR myopathy (N = 55)
Maintenance of remission with SSI monotherapy | Univariate | Multivariate | ||
|---|---|---|---|---|
Yes (n = 30), n (%) or Median (range) | No (n = 25), n (%) or Median (range) | OR (95% CI), P value | OR (95% CI), P value | |
Age at treatment initiation, Median (range) years | 68.2 (48.5–86.1) | 66.9 (44.0–83.1) | 1.02 (0.97 to 1.08), P = 0.516 | – |
Male sex, n (%) | 17 (57) | 13 (52) | 1.21 (0.41 to 3.54), P = 0.729 | – |
Normal strength at treatment initiation, n (%) | 5 (17) | 4 (16) | 1.05 (0.25 to 4.72), P = 0.947 | – |
CK at treatment initiation, Median (range) UI/L | 4959 (554–23,000) | 5083 (1533–14,098) | 1.00 (1.00 to 1.00), P = 0.582 | – |
Dysphagia, subjective, n (%) | 9 (30) | 7 (28) | 1.10 (0.34 to 3.65), P = 0.871 | – |
Dysphagia, objective, n (%) | 1 (3) | 4 (16) | 0.18 (0.01 to 1.33), P = 0.139 | – |
Delay between first increased serum CK and treatment initiation, Median (range) months | 2.0 (0–24.9) | 11.0 (0–95.0) | 0.94 (0.88 to 0.98), P = 0.025 | 0.92 (0.85 to 0.97), P = 0.015 |
Use of corticosteroids in induction, n (%) | 23 (77) | 18 (72) | 1.28 (0.37 to 4.39), P = 0.693 | – |
Use of IVIG in induction, n (%) | 10 (33) | 19 (76) | 0.16 (0.04 to 0.50), P = 0.002 | 0.08 (0.01 to 0.32), P = 0.001 |